Celldex Therapeutics Inc. (Nasdaq: CLDX) reported disappointing results from a Phase 2b METRIC study of glembatumumab vedotin sending the stock price plummeting $1.38 to close at $0.76.
Disappointing study results for Celldex Therapeutics
April 16, 2018 at 19:08 PM EDT
